SEOM Clinical Guideline for the Management of Malignant Melanoma (2017)

Clin Transl Oncol. 2018 Jan;20(1):69-74. doi: 10.1007/s12094-017-1768-1. Epub 2017 Nov 7.

Abstract

All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.

Keywords: Adjuvant; B-RAF; Immunotherapy; Melanoma; Metastatic.

Publication types

  • Practice Guideline

MeSH terms

  • Combined Modality Therapy / methods
  • Humans
  • Melanoma / therapy*